233 related articles for article (PubMed ID: 25973178)
1. Treatment of the later stages of Parkinson's disease - pharmacological approaches now and in the future.
Jenner P
Transl Neurodegener; 2015; 4():3. PubMed ID: 25973178
[TBL] [Abstract][Full Text] [Related]
2. New pharmacological options for treating advanced Parkinson's disease.
Devos D; Moreau C; Dujardin K; Cabantchik I; Defebvre L; Bordet R
Clin Ther; 2013 Oct; 35(10):1640-52. PubMed ID: 24011636
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Parkinson's disease: levodopa as the first choice.
Katzenschlager R; Lees AJ
J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
[TBL] [Abstract][Full Text] [Related]
4. Moving from continuous dopaminergic stimulation to continuous drug delivery in the treatment of Parkinson's disease.
Gershanik O; Jenner P
Eur J Neurol; 2012 Dec; 19(12):1502-8. PubMed ID: 22221452
[TBL] [Abstract][Full Text] [Related]
5. Wearing off, dyskinesia, and the use of continuous drug delivery in Parkinson's disease.
Jenner P
Neurol Clin; 2013 Aug; 31(3 Suppl):S17-35. PubMed ID: 23931952
[TBL] [Abstract][Full Text] [Related]
6. New treatments for levodopa-induced motor complications.
Rascol O; Perez-Lloret S; Ferreira JJ
Mov Disord; 2015 Sep; 30(11):1451-60. PubMed ID: 26293004
[TBL] [Abstract][Full Text] [Related]
7. An overview of adenosine A2A receptor antagonists in Parkinson's disease.
Jenner P
Int Rev Neurobiol; 2014; 119():71-86. PubMed ID: 25175961
[TBL] [Abstract][Full Text] [Related]
8. Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours.
Lhommée E; Klinger H; Thobois S; Schmitt E; Ardouin C; Bichon A; Kistner A; Fraix V; Xie J; Aya Kombo M; Chabardès S; Seigneuret E; Benabid AL; Mertens P; Polo G; Carnicella S; Quesada JL; Bosson JL; Broussolle E; Pollak P; Krack P
Brain; 2012 May; 135(Pt 5):1463-77. PubMed ID: 22508959
[TBL] [Abstract][Full Text] [Related]
9. New treatments for the motor symptoms of Parkinson's disease.
Vijverman AC; Fox SH
Expert Rev Clin Pharmacol; 2014 Nov; 7(6):761-77. PubMed ID: 25318835
[TBL] [Abstract][Full Text] [Related]
10. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease.
Warren Olanow C; Kieburtz K; Rascol O; Poewe W; Schapira AH; Emre M; Nissinen H; Leinonen M; Stocchi F;
Mov Disord; 2013 Jul; 28(8):1064-71. PubMed ID: 23630119
[TBL] [Abstract][Full Text] [Related]
11. Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson's Disease Fluctuating Patients: Post hoc Analyses of Studies 016 and SETTLE.
Cattaneo C; Sardina M; Bonizzoni E
J Parkinsons Dis; 2016; 6(1):165-73. PubMed ID: 26889632
[TBL] [Abstract][Full Text] [Related]
12. Non-Oral Drug Delivery in Parkinson's Disease: Current Applications and Future.
Güneş M; Karavana SY
Turk J Pharm Sci; 2022 Jun; 19(3):343-352. PubMed ID: 35775493
[TBL] [Abstract][Full Text] [Related]
13. [Significant improvement of motor symptoms by deep brain stimulation of bilateral subthalamic nucleus in patients with moderate or advanced Parkinson's disease].
Chen J; Liu JL; Chen X; Qian H; Xian WB; Zhou HY; Liu YM; Ye XF; Zheng YF; Zhang SL; Chen L; Li JR; Liu ZL; Pei Z
Zhonghua Yi Xue Za Zhi; 2011 Feb; 91(5):291-5. PubMed ID: 21419000
[TBL] [Abstract][Full Text] [Related]
14. Management for motor and non-motor complications in late Parkinson's disease.
Chan DK; Cordato DJ; O'Rourke F
Geriatrics; 2008 May; 63(5):22-7. PubMed ID: 18447408
[TBL] [Abstract][Full Text] [Related]
15. Lack of depotentiation at basal ganglia output neurons in PD patients with levodopa-induced dyskinesia.
Prescott IA; Liu LD; Dostrovsky JO; Hodaie M; Lozano AM; Hutchison WD
Neurobiol Dis; 2014 Nov; 71():24-33. PubMed ID: 25116960
[TBL] [Abstract][Full Text] [Related]
16. Different effects of dopaminergic medication on perceptual decision-making in Parkinson's disease as a function of task difficulty and speed-accuracy instructions.
Huang YT; Georgiev D; Foltynie T; Limousin P; Speekenbrink M; Jahanshahi M
Neuropsychologia; 2015 Aug; 75():577-87. PubMed ID: 26184442
[TBL] [Abstract][Full Text] [Related]
17. Interaction of adenosine receptors with other receptors from therapeutic perspective in Parkinson's disease.
Morin N; Di Paolo T
Int Rev Neurobiol; 2014; 119():151-67. PubMed ID: 25175965
[TBL] [Abstract][Full Text] [Related]
18. Contribution of brain serotonin subtype 1B receptors in levodopa-induced motor complications.
Morin N; Morissette M; Grégoire L; Rajput A; Rajput AH; Di Paolo T
Neuropharmacology; 2015 Dec; 99():356-68. PubMed ID: 26254863
[TBL] [Abstract][Full Text] [Related]
19. The rationale for continuous dopaminergic stimulation in advanced Parkinson's disease.
Nyholm D
Parkinsonism Relat Disord; 2007 Sep; 13 Suppl():S13-7. PubMed ID: 17707679
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological approaches to disease-modifying therapies in Parkinson's disease.
O'Neill MJ; Siemers ER
Expert Rev Neurother; 2002 Nov; 2(6):819-34. PubMed ID: 19810916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
